Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome
Background. CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological...
Saved in:
Main Authors: | Khaled Abd Elaziz Ahmed Elnaghi, Hosam Ali Alghanmi, Shereef Ahmed Elsamany, Fathia Almarzoki, Mohamed Elsafty, Mohammad Jaffal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-01-01
|
Series: | The Breast Journal |
Online Access: | http://dx.doi.org/10.1155/2023/8994954 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer
by: Akshara Singareeka Raghavendra, et al.
Published: (2025-01-01) -
Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial
by: Jianli Zhao, et al.
Published: (2025-01-01) -
Thyroid hormones and neurological impairments during the first two days after stroke: A pilot study
by: Kobra Akhoundzadeh, et al.
Published: (2025-01-01) -
The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01) -
The Decreased Growth Hormone Response to Growth Hormone Releasing Hormone in Obesity Is Associated to Cardiometabolic Risk Factors
by: Fernando Cordido, et al.
Published: (2010-01-01)